Pfizer: EU approves Vyndaqel for rare heart disease

(CercleFinance.com) - Pfizer said that the European Commission has approved Vyndaqel, a once-daily oral pill, for the treatment of transthyretin amyloid cardiomyopathy, a rare heart disease.


The US drugmaker said Vyndaqel has hence become the first and only treatment approved in the European Union for patients with wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Prior to this approval, treatment options for patients with ATTR-CM were restricted to symptom management, and, in rare cases, heart transplants.

ATTR-CM is characterised by the buildup of abnormal deposits of protein called amyloid in the heart. Once diagnosed, the median life expectancy in patients is approximately two to 3.5 years, Pfizer said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.